ROIVANT SCIENCES LTD. Operating Cash Flow
ROIVANT SCIENCES LTD. (ROIV) reported Operating Cash Flow of -$270.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$270.50M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$163.82M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$196.48M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$185.66M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2026 was -$750.35M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2025 was -$839.45M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2024 was -$765.27M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) operating activities for fiscal 2023 was -$843.39M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$270.50M 10-Q · filed 2026-08-06 | -$434.32M derived: sum of 2 quarters · filed 2026-08-06 | -$630.81M derived: sum of 3 quarters · filed 2026-08-06 | -$816.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$163.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$360.30M derived: sum of 2 quarters · filed 2026-05-20 | -$545.97M derived: sum of 3 quarters · filed 2026-05-20 | -$750.35M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$196.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$382.15M derived: sum of 2 quarters · filed 2026-02-06 | -$586.53M 10-Q · filed 2026-02-06 | -$759.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$185.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$390.05M 10-Q · filed 2025-11-10 | -$562.61M derived: sum of 3 quarters · filed 2026-08-06 | -$769.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$204.38M 10-Q · filed 2026-08-06 | -$376.95M derived: sum of 2 quarters · filed 2026-08-06 | -$584.20M derived: sum of 3 quarters · filed 2026-08-06 | -$851.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$172.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$379.82M derived: sum of 2 quarters · filed 2026-05-20 | -$646.62M derived: sum of 3 quarters · filed 2026-05-20 | -$839.45M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$207.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$474.06M derived: sum of 2 quarters · filed 2026-02-06 | -$666.89M 10-Q · filed 2026-02-06 | -$775.34M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$266.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$459.63M 10-Q · filed 2025-11-10 | -$568.09M derived: sum of 3 quarters · filed 2026-05-20 | -$778.54M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$192.83M 10-Q · filed 2025-08-11 | -$301.29M derived: sum of 2 quarters · filed 2026-05-20 | -$511.74M derived: sum of 3 quarters · filed 2026-05-20 | -$708.16M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$108.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$318.91M derived: sum of 2 quarters · filed 2026-05-20 | -$515.34M derived: sum of 3 quarters · filed 2026-05-20 | -$765.27M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$210.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | -$406.88M derived: sum of 2 quarters · filed 2025-02-10 | -$656.81M 10-Q · filed 2025-02-10 | -$835.90M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$196.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$446.36M 10-Q · filed 2024-11-12 | -$625.45M derived: sum of 3 quarters · filed 2025-05-29 | -$848.04M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$249.93M 10-Q · filed 2024-08-09 | -$429.02M derived: sum of 2 quarters · filed 2025-05-29 | -$651.61M derived: sum of 3 quarters · filed 2025-05-29 | -$841.24M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$179.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$401.68M derived: sum of 2 quarters · filed 2025-05-29 | -$591.31M derived: sum of 3 quarters · filed 2025-05-29 | -$843.39M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$222.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | -$412.22M derived: sum of 2 quarters · filed 2024-02-13 | -$664.30M 10-Q · filed 2024-02-13 | -$811.77M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$189.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$441.71M 10-Q · filed 2023-11-13 | -$589.18M derived: sum of 3 quarters · filed 2023-11-13 | -$857.67M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$252.08M 10-Q · filed 2023-08-14 | -$399.55M derived: sum of 2 quarters · filed 2023-08-14 | -$668.04M derived: sum of 3 quarters · filed 2023-08-14 | -$788.64M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$147.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$415.96M derived: sum of 2 quarters · filed 2023-06-28 | -$536.56M derived: sum of 3 quarters · filed 2023-06-28 | -$677.73M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$268.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | -$389.09M derived: sum of 2 quarters · filed 2023-02-13 | -$530.26M 10-Q · filed 2023-02-13 | -$636.33M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | -$120.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$261.77M 10-Q · filed 2022-11-14 | -$367.83M derived: sum of 3 quarters · filed 2022-11-14 | -$604.69M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$141.17M 10-Q · filed 2022-08-15 | -$247.24M derived: sum of 2 quarters · filed 2022-08-15 | -$484.10M derived: sum of 3 quarters · filed 2022-08-15 | -$582.14M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$106.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$342.93M derived: sum of 2 quarters · filed 2022-06-28 | -$440.97M derived: sum of 3 quarters · filed 2022-06-28 | -$552.14M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$236.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | -$334.90M derived: sum of 2 quarters · filed 2022-02-14 | -$446.07M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$98.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$209.21M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$111.17M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |